Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily.

Trial Profile

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2013

At a glance

  • Drugs Trospium chloride (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 11 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 22 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top